US President Donald Trump’s plan to cut foreign aid supporting HIV/Aids treatment could cost 9 million years of lost life in South Africa and Ivory Coast, according to a global study released on Monday.
In the first study to measure the impact of cuts in global investment in HIV care in terms of health and costs, scientists found sky-rocketing deaths in the African nations would far outweigh savings.
South Africa has the highest prevalence of HIV worldwide, with 19% of its adult population carrying the virus in 2015, according to UNAIDS, with a total of 7 million HIV-infected people.
Ivory Coast counted 460,000 HIV-infected people in that same year.
Trump’s proposed budget for 2018, made public in May, envisions cuts to the President’s Emergency Plan for Aids Relief (PEPFAR) program, a cornerstone of US global health assistance, which supports HIV/Aids treatment, testing and counseling for millions of people worldwide.
Under Trump’s budget, which pursues his “America First” world view, PEPFAR funding would be $5 billion per year compared to about $6 billion annually now, the US State Department has said. No patient currently receiving antiretroviral therapy, a treatment for HIV, through PEPFAR funds will lose that treatment, officials have said.
Should the cuts keep South Africans and Ivorians from receiving antiretroviral drugs, an additional 1.8 million HIV-infected people would die over the next 10 years, 11 researchers in America, Europe, and Africa concluded, using mathematical models.
The combined deaths amount to nearly 9 million years of life lost, the scientists calculated, in what they said was the first effort to put figures on the proposed cuts.
The researchers measured expected savings over the next decade, whose small scale they said raised efficacy and ethical questions. In South Africa, it would amount to some $900 per year of life lost, compared to $600 to $900 in Ivory Coast.
“We leave it to readers to draw their own conclusions about whether imposing such tradeoffs on vulnerable populations accurately reflects how donor countries value life in recipient nations,” the researchers wrote in Annals of Internal Medicine.
Savings would eventually dry up over the decade, they found, due to higher costs tied to the spread of HIV amid scaled back screening and care.
“Would the relatively small savings realized by currently proposed budget reductions be worth these large humanitarian costs?” said lead author Rochelle Walensky, a professor of medicine at Harvard Medical School.
“Over the past decade and a half, we’ve spent considerable money to save lives in these and other African nations.”
Some 90% of Ivory Coast’s funding for HIV care and prevention depends on international aid, while South Africa self-financed most of its HIV expenditures, according to US government figures.
